U.S. Markets close in 34 mins
  • S&P 500

    3,627.12
    -91.92 (-2.47%)
     
  • Dow 30

    29,143.65
    -540.09 (-1.82%)
     
  • Nasdaq

    10,679.73
    -371.91 (-3.37%)
     
  • Russell 2000

    1,662.04
    -53.20 (-3.10%)
     
  • Crude Oil

    81.52
    -0.63 (-0.77%)
     
  • Gold

    1,667.90
    -2.10 (-0.13%)
     
  • Silver

    18.77
    -0.11 (-0.58%)
     
  • EUR/USD

    0.9802
    +0.0063 (+0.6469%)
     
  • 10-Yr Bond

    3.7470
    +0.0420 (+1.13%)
     
  • Vix

    32.59
    +2.41 (+7.99%)
     
  • GBP/USD

    1.1065
    +0.0179 (+1.6464%)
     
  • USD/JPY

    144.3960
    +0.2740 (+0.1901%)
     
  • BTC-USD

    19,390.77
    -119.83 (-0.61%)
     
  • CMC Crypto 200

    443.37
    -2.61 (-0.59%)
     
  • FTSE 100

    6,881.59
    -123.80 (-1.77%)
     
  • Nikkei 225

    26,422.05
    +248.07 (+0.95%)
     

FDA Gives Green Signal To Provention Bio's Delaying Diabetes Med Resubmission

·1 min read

Provention Bio Inc (NASDAQ: PRVB) said that it had resolved the comparability concerns with the FDA, and teplizumab is clear for resubmission.

  • The resubmission should be ready to go in Q1 of FY22.

  • After discussions with the FDA, Provention agreed to use pharmacokinetic modeling to adjust the 14-day dosing regimen for the commercial product to match the exposure seen with the material used in the treatment's clinical trials.

  • The Company will propose a modified 14-day course to address the FDA's concerns.

  • The resubmission will also include responses to the FDA's questions about chemical, manufacturing, and controls, along with product quality considerations. The type A meeting was held in August last year.

  • The therapy narrowly passed the vote at an FDA advisory committee meeting in May last year amid questions about the small study size and more.

  • The FDA hit teplizumab with a complete response letter, rejecting the application.

  • The agency questioned data related to the drug substance to be used in the commercial product and asked for a safety update in a resubmission.

  • Price Action: PRVB shares are up 11.8% at $3.80 during the premarket session on the last check Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.